TWI355935B - Combination of a taxane and a cyclin-dependent kin - Google Patents

Combination of a taxane and a cyclin-dependent kin Download PDF

Info

Publication number
TWI355935B
TWI355935B TW091105567A TW91105567A TWI355935B TW I355935 B TWI355935 B TW I355935B TW 091105567 A TW091105567 A TW 091105567A TW 91105567 A TW91105567 A TW 91105567A TW I355935 B TWI355935 B TW I355935B
Authority
TW
Taiwan
Prior art keywords
days
administered
patent application
docetaxel
floripone
Prior art date
Application number
TW091105567A
Other languages
English (en)
Chinese (zh)
Inventor
Bissery Marie-Christine
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of TWI355935B publication Critical patent/TWI355935B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW091105567A 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kin TWI355935B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04

Publications (1)

Publication Number Publication Date
TWI355935B true TWI355935B (en) 2012-01-11

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091105567A TWI355935B (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kin

Country Status (33)

Country Link
US (2) US20020182204A1 (enExample)
EP (1) EP1372652B1 (enExample)
JP (1) JP2004521140A (enExample)
KR (1) KR100879712B1 (enExample)
CN (1) CN1498107A (enExample)
AR (1) AR034222A1 (enExample)
AT (1) ATE395917T1 (enExample)
AU (1) AU2002312815B2 (enExample)
BR (1) BR0208221A (enExample)
CA (1) CA2441441C (enExample)
CY (1) CY1110449T1 (enExample)
CZ (1) CZ301423B6 (enExample)
DE (1) DE60226710D1 (enExample)
DK (1) DK1372652T3 (enExample)
EA (1) EA007815B1 (enExample)
ES (1) ES2305253T3 (enExample)
HR (1) HRPK20030766B3 (enExample)
HU (1) HU229258B1 (enExample)
IL (2) IL158058A0 (enExample)
ME (1) MEP16408A (enExample)
MX (1) MXPA03007743A (enExample)
NO (1) NO332441B1 (enExample)
NZ (1) NZ527655A (enExample)
PE (1) PE20020907A1 (enExample)
PL (1) PL206118B1 (enExample)
PT (1) PT1372652E (enExample)
RS (1) RS50681B (enExample)
SI (1) SI1372652T1 (enExample)
SK (1) SK287481B6 (enExample)
TW (1) TWI355935B (enExample)
UY (1) UY27220A1 (enExample)
WO (1) WO2002076484A2 (enExample)
ZA (1) ZA200307381B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
EP1558242B1 (en) * 2002-11-06 2008-12-24 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
ES2390237T3 (es) * 2006-02-10 2012-11-07 Nerviano Medical Sciences S.R.L. Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
BR112013012313A2 (pt) * 2010-11-19 2019-09-24 Piramal Enterprises Limited combinação farmacêutica de paclitaxel e um inibidor de cdk
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0888458A4 (en) * 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER

Also Published As

Publication number Publication date
NO20034124L (no) 2003-09-16
UY27220A1 (es) 2002-09-30
PT1372652E (pt) 2008-07-24
SK11692003A3 (sk) 2004-03-02
ATE395917T1 (de) 2008-06-15
DE60226710D1 (de) 2008-07-03
CY1110449T1 (el) 2015-04-29
HUP0303589A2 (hu) 2004-03-01
WO2002076484A3 (en) 2003-01-03
KR100879712B1 (ko) 2009-01-22
MXPA03007743A (es) 2004-11-12
BR0208221A (pt) 2004-03-02
EA007815B1 (ru) 2007-02-27
EP1372652B1 (en) 2008-05-21
IL158058A (en) 2010-02-17
NZ527655A (en) 2006-03-31
RS50681B (sr) 2010-06-30
ZA200307381B (en) 2005-03-30
CA2441441C (en) 2009-05-26
KR20030086318A (ko) 2003-11-07
JP2004521140A (ja) 2004-07-15
PL206118B1 (pl) 2010-07-30
HUP0303589A3 (en) 2007-05-02
US20060128640A1 (en) 2006-06-15
CN1498107A (zh) 2004-05-19
SI1372652T1 (sl) 2008-10-31
YU69503A (sh) 2006-08-17
US20020182204A1 (en) 2002-12-05
PL367702A1 (en) 2005-03-07
CA2441441A1 (en) 2002-10-03
EA200301053A1 (ru) 2004-02-26
ES2305253T3 (es) 2008-11-01
SK287481B6 (sk) 2010-11-08
DK1372652T3 (da) 2008-09-22
CZ20032551A3 (en) 2004-07-14
HRPK20030766B3 (en) 2006-11-30
NO20034124D0 (no) 2003-09-16
PE20020907A1 (es) 2002-12-19
NO332441B1 (no) 2012-09-17
HRP20030766A2 (en) 2005-06-30
EP1372652A2 (en) 2004-01-02
HU229258B1 (en) 2013-10-28
AU2002312815B2 (en) 2006-08-24
CZ301423B6 (cs) 2010-02-24
MEP16408A (en) 2010-10-10
AR034222A1 (es) 2004-02-04
WO2002076484A2 (en) 2002-10-03
IL158058A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
JP7660595B2 (ja) Ｃｙｐ２ｃ８及びｃｙｐ３ａ４の二重基質、糖質コルチコイド・レセプター・モジュレーターのリラコリラント及びパクリタキセルの併用投与
WO2010081817A1 (en) Method for treating colorectal cancer
WO2020049139A1 (en) Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
US10213436B2 (en) Methods of treating cancer using aurora kinase inhibitors
ES3030540T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
JP2006504721A (ja) 治療剤に対する乳癌耐性タンパク質（ｂｃｒｐ）−介在耐性を阻害するためのイマチニブ（グリベック、ｓｔｉ−５７１）の使用
KR100879712B1 (ko) 탁산과 사이클린-의존성 키나제 억제제와의 병용제제
JP7493503B2 (ja) Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物
JP7332589B2 (ja) 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
AU2002312815A1 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
JP4429732B2 (ja) 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
JP7536118B2 (ja) グルココルチコイド受容体モジュレーターレラコリラントおよびｃｙｐ２ｃ８基質の併用投与
Bandivadekar et al. Cdk 4/6 inhibitors revolutionized breast cancer therapy
JP2024165887A (ja) Ｔｃｆ３－ｈｌｆ型ｂ細胞性急性リンパ性白血病の治療剤
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
CN101198253A (zh) 治疗癌症的组合、方法和组合物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees